The new drug is part of the second-generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections
plans to move a reworked, once-a-day version of its weight loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year.
Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, to be worth more than $150 billion in annual sales by the early 2030s. It had already dropped another daily weight loss drug, called lotiglipron, due to safety concerns as it raised levels of liver enzymes in some patients.The shares closed at $28.35 on Wednesday and have lost more than half of their value since hitting $61 in December 2021, due to a steep drop in sales of its COVID products and investor worries over its pipeline including lotiglipron.
Canada News Breaking News Video Canadian Breaking News Breaking News Globe And Mail Breaking News Globe And Mail Canada News Photos World News Local News National News Us News Foreign News Sports News Arts News Life News Lifestyle Canada Traffic Canada Weather Trudeau Government Federal Government Canada Sports Canada Sports News Politics Politics News Political News Political Opinion Environment Economy Technology Education Travel Canada Alberta Bc British Columbia Manitoba Ontario Quebec Nova Scotia Pei New Brunswick Newfoundland And Labrador Nunavut Northwest Territories Yukon Globe And Mail
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk, Eli Lilly still top 2 pharma stocks: AnalystNovo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as...
Read more »
Innovent’s Obesity Drug Shows Similar Weight Loss as Eli Lilly’sA new obesity drug co-developed by China’s Innovent Biologics Inc. and Eli Lilly & Co. has demonstrated significant weight loss in a late stage trial, paying the way for its approval in the country to compete with the blockbuster from Novo Nordisk A/S.
Read more »
WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugsCP24 is your source for breaking news headlines from around the world, including on the Israel-Hamas war, the India-Canada rift and the war between Russia and Ukraine.
Read more »
WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugsThe World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines.
Read more »
Eli Lilly Broadens Crackdown on Fake and Compounded ZepboundEli Lilly & Co. broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of the treatment.
Read more »
Eli Lilly unveils new North Carolina plant for GLP-1 drugsEli Lilly and Company (LLY) unveiled a new manufacturing plant in North Carolina on Friday, which, according to the pharmaceutical giant, is expected to...
Read more »